Grail files for FDA approval of multi-cancer early detection test
Premarket approval could help the company secure coverage from commercial payers and Medicare.
Grail files for FDA approval of multi-cancer early detection test Read More »
Uncategorized
GSK Hands RNA Editor Back to Wave After Underwhelming Early AATD Data
While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in September 2025 came below analyst expectations in a Phase Ib/IIa AATD study.
GSK Hands RNA Editor Back to Wave After Underwhelming Early AATD Data Read More »
Amgen Ends Autoimmune Alliance With Kyowa Kirin Amid Safety, Efficacy Questions
A Phase III readout in September 2024 for rocatinlimab, on which Amgen and Kyowa Kirin were collaborating in atopic dermatitis, appeared underwhelming to analysts, with Jefferies noting that the data “came in at the lower end of efficacy and expectations.”
Amgen Ends Autoimmune Alliance With Kyowa Kirin Amid Safety, Efficacy Questions Read More »
FDA Warned Corcept of ‘Significant Review Issues’ for Rejected Drug in Early Meetings
Corcept’s relacorilant was rejected for hypercortisolism late last year—a decision which CEO Joseph Belanoff expressed surprise with at the time.
FDA Warned Corcept of ‘Significant Review Issues’ for Rejected Drug in Early Meetings Read More »
FDA Launches PreCheck Program, Intended To Bring Manufacturers Home
The program will allow for frequent communication with the FDA, giving manufacturers timely input and guidance regarding the design of their facilities.
FDA Launches PreCheck Program, Intended To Bring Manufacturers Home Read More »
Sanofi Rare Disease Drug Scores a Hit and a Miss in Phase III Tests
Sanofi will take venglustat to regulators for Gaucher disease but an application for Fabry disease is less clear after the failure of a Phase III trial.
Sanofi Rare Disease Drug Scores a Hit and a Miss in Phase III Tests Read More »
Eli Lilly Commits $3.5B To Build Injectable Obesity Drug Plant in PA
The facility, which is part of Lilly’s $50 billion reshoring drive, will make obesity drugs such as tirzepatide and retatrutide when it starts operations in 2031.
Eli Lilly Commits $3.5B To Build Injectable Obesity Drug Plant in PA Read More »
Por qué tu cuerpo no está absorbiendo los suplementos que tomas
Gastas dinero en vitaminas cada mes. Las tomas religiosamente con el desayuno. Pero hay un problema del que casi nadie habla: la mayoría de los suplementos que consumes terminan siendo eliminados por tu cuerpo sin aprovecharse realmente. No es tu culpa. Es biología. E …
Por qué tu cuerpo no está absorbiendo los suplementos que tomas Read More »
Francis Crick: el científico que descifró el código de la vida
Cuando hoy hablamos de genética, ADN o biología molecular, es imposible no mencionar a Francis Crick. Su nombre está ligado para siempre a uno de los mayores descubrimientos científicos del siglo XX: la estructura de la doble hélice del ADN, la molécula que …
Francis Crick: el científico que descifró el código de la vida Read More »
Satélites vulnerables a los hackers, vórtices polares de Júpiter y de Saturno, lunas hermanas
Noticias de la actualidad astronómica y astronáutica del 2 de febrero de 2026. …